LON:RENX Renalytix (RENX) Share Price, News & Analysis GBX 8 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlines About Renalytix Stock (LON:RENX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Renalytix alerts:Sign Up Key Stats Today's Range 8▼ 850-Day Range 7.38▼ 11.2552-Week Range 7▼ 74.90Volume632,837 shsAverage Volume449,572 shsMarket Capitalization£13.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Receive RENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address RENX Stock News HeadlinesChristopher H. B. Mills Sells 83,696 Shares of Renalytix Plc (LON:RENX) StockOctober 13, 2024 | insidertrades.comCommencement of trading on OTCQB in the United StatesOctober 8, 2024 | finance.yahoo.comWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…November 2, 2024 | Porter & Company (Ad)Renalytix (NASDAQ:RNLX) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comRenalytix AI plc (2O9.MU)August 29, 2024 | uk.finance.yahoo.comLatest News for Renalytix Stock (NASDAQ:RNLX)May 28, 2024 | benzinga.comIs Renalytix the best penny stock to buy today?March 9, 2024 | uk.finance.yahoo.comRNLX Mar 2024 2.500 callFebruary 17, 2024 | finance.yahoo.comSee More Headlines RENX Stock Analysis - Frequently Asked Questions How have RENX shares performed this year? Renalytix's stock was trading at GBX 15.50 at the beginning of the year. Since then, RENX shares have decreased by 48.4% and is now trading at GBX 8. View the best growth stocks for 2024 here. How do I buy shares of Renalytix? Shares of RENX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Renalytix investors own include AutoZone (AZO), Beyond Meat (BYND), Helium One Global (HE1), HSBC (HSBA), Intel (INTC), ITM Power (ITM) and JD Sports Fashion (JD). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolLON:RENX CUSIPN/A CIKN/A Webwww.renalytixai.com Phone44 20 3139 2910FaxN/AEmployees102Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-33,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,073.18% Return on Assets-93.54% Debt Debt-to-Equity Ratio173.95 Current Ratio0.53 Quick Ratio2.42 Sales & Book Value Annual Sales£2.29 million Price / Sales5.80 Cash FlowGBX 4.36 per share Price / Cash Flow1.84 Book ValueGBX (5) per share Price / Book-1.60Miscellaneous Outstanding Shares165,930,000Free FloatN/AMarket Cap£13.27 million OptionableNot Optionable Beta2.10 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report This page (LON:RENX) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.